179 related articles for article (PubMed ID: 35821104)
1. Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.
Peter E; Treilleux I; Wucher V; Jougla E; Vogrig A; Pissaloux D; Paindavoine S; Berthet J; Picard G; Rogemond V; Villard M; Vincent C; Tonon L; Viari A; Honnorat J; Dubois B; Desestret V
Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35821104
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.
Small M; Treilleux I; Couillault C; Pissaloux D; Picard G; Paindavoine S; Attignon V; Wang Q; Rogemond V; Lay S; Ray-Coquard I; Pfisterer J; Joly F; Du Bois A; Psimaras D; Bendriss-Vermare N; Caux C; Dubois B; Honnorat J; Desestret V
Acta Neuropathol; 2018 Apr; 135(4):569-579. PubMed ID: 29299667
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration.
Rojas-Marcos I; Picard G; Chinchón D; Gelpi E; Psimaras D; Giometto B; Delattre JY; Honnorat J; Graus F
Neuro Oncol; 2012 Apr; 14(4):506-10. PubMed ID: 22351748
[TBL] [Abstract][Full Text] [Related]
4. Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies.
Winklehner M; Bauer J; Endmayr V; Schwaiger C; Ricken G; Motomura M; Yoshimura S; Shintaku H; Ishikawa K; Tsuura Y; Iizuka T; Yokota T; Irioka T; Höftberger R
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 36070310
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.
Vialatte de Pémille C; Berzero G; Small M; Psimaras D; Giry M; Daniau M; Sanson M; Delattre JY; Honnorat J; Desestret V; Alentorn A
Br J Cancer; 2018 Jul; 119(1):105-113. PubMed ID: 29899393
[TBL] [Abstract][Full Text] [Related]
6. A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration.
Erikstad KI; Herdlevaer I; Peter E; Haugen M; Totland C; Vedeler C
Eur J Neurol; 2023 Jun; 30(6):1727-1733. PubMed ID: 36912432
[TBL] [Abstract][Full Text] [Related]
7. Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.
Raspotnig M; Haugen M; Thorsteinsdottir M; Stefansson I; Salvesen HB; Storstein A; Vedeler CA
Cancer Immunol Immunother; 2017 Nov; 66(11):1463-1471. PubMed ID: 28710511
[TBL] [Abstract][Full Text] [Related]
8. CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.
Eichler TW; Totland C; Haugen M; Qvale TH; Mazengia K; Storstein A; Haukanes BI; Vedeler CA
PLoS One; 2013; 8(6):e66002. PubMed ID: 23823982
[TBL] [Abstract][Full Text] [Related]
9. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review.
Le May M; Dent S
Curr Oncol; 2018 Dec; 25(6):e585-e591. PubMed ID: 30607127
[TBL] [Abstract][Full Text] [Related]
10. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
Yshii L; Bost C; Liblau R
Front Immunol; 2020; 11():991. PubMed ID: 32655545
[TBL] [Abstract][Full Text] [Related]
11. CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration.
Kråkenes T; Herdlevaer I; Raspotnig M; Haugen M; Schubert M; Vedeler CA
Ann Neurol; 2019 Aug; 86(2):316-321. PubMed ID: 31148214
[TBL] [Abstract][Full Text] [Related]
12. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.
Panja D; Vedeler CA; Schubert M
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):141-156. PubMed ID: 29679372
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies.
Peter E; Honnorat J; Desestret V
Handb Clin Neurol; 2024; 200():409-417. PubMed ID: 38494293
[TBL] [Abstract][Full Text] [Related]
14. Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies.
Hillary RP; Ollila HM; Lin L; Desestret V; Rogemond V; Picard G; Small M; Arnulf I; Dauvilliers Y; Honnorat J; Mignot E
J Neuroimmunol; 2018 Feb; 315():28-32. PubMed ID: 29306402
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.
Herdlevær I; Haugen M; Mazengia K; Totland C; Vedeler C
Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33531379
[TBL] [Abstract][Full Text] [Related]
16. Paraneoplastic cerebellar degeneration with anti-Yo antibodies and an associated submandibular gland tumor: a case report.
Imai T; Shinohara K; Uchino K; Okuma H; Maki F; Hiruma K; Ariizumi Y; Yamano Y
BMC Neurol; 2022 May; 22(1):165. PubMed ID: 35501715
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.
Shams'ili S; Grefkens J; de Leeuw B; van den Bent M; Hooijkaas H; van der Holt B; Vecht C; Sillevis Smitt P
Brain; 2003 Jun; 126(Pt 6):1409-18. PubMed ID: 12764061
[TBL] [Abstract][Full Text] [Related]
18. [A case of slowly progressive anti-Yo-associated paraneoplastic cerebellar degeneration successfully treated with antitumor and immunotherapy].
Tsuboguchi S; Yajima R; Higuchi Y; Ishikawa M; Kawachi I; Koyama Y; Nishizawa M
Rinsho Shinkeigaku; 2016 Jul; 56(7):477-80. PubMed ID: 27356731
[TBL] [Abstract][Full Text] [Related]
19. Paraneoplastic cerebellar degeneration with anti-Yo antibody in a patient with HER2/neu overexpressing breast cancer: a case report with a current literature review.
Ogita S; Llaguna OH; Feldman SM; Blum R
Breast J; 2008; 14(4):382-4. PubMed ID: 18540952
[TBL] [Abstract][Full Text] [Related]
20. CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity.
Vorasoot N; Scharf M; Miske R; Thakolwiboon S; Dubey D; Mills JR; Pittock SJ; Zekeridou A; Ott A; McKeon A
Front Immunol; 2023; 14():1265797. PubMed ID: 37841252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
